[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637456":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":54,"collaborators":56,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rectosigmoid Lesion Excision","EXPERIMENTAL","rectosigmoid lesion excision +tumor cell debulking surgery",[13],"Procedure: Rectosigmoid Lesion Excision +tumor cell debulking surgery",{"label":15,"type":16,"description":17,"interventionNames":18},"Rectosigmoid Resection","ACTIVE_COMPARATOR","rectosigmoid resection +tumor cell debulking surgery",[19],"Procedure: Rectosigmoid Resection +tumor cell debulking surgery",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Rectosigmoid Lesion Excision +tumor cell debulking surgery","Surgery for pelvic rectosigmoid tumors",[9],null,{"type":22,"name":28,"description":28,"armGroupLabels":29,"otherNames":26},"Rectosigmoid Resection +tumor cell debulking surgery",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Jing Fei","CONTACT","+86 13732238958","feijing@zju.edu.cn",{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},"Zhigang Zhang","+86 15088621550","zzg2011@zju.edu.cn",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":26},"RECRUITING","Hangzhou","Zhejiang","310000","China","CN",{"type":49,"coordinates":50},"Point",[51,52],120.16142,30.29365,{"lat":52,"lon":51},{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[57,59,61,63,65,67,69,71,73],{"name":58,"class":6},"Tongji Hospital",{"name":60,"class":6},"Zhejiang University",{"name":62,"class":6},"Zhejiang Provincial People's Hospital",{"name":64,"class":6},"Zhejiang Cancer Hospital",{"name":66,"class":6},"Huzhou Central Hospital",{"name":68,"class":6},"Ningbo Women & Children's Hospital",{"name":70,"class":6},"Shaoxing People's Hospital",{"name":72,"class":6},"The Central Hospital of Lishui City",{"name":74,"class":6},"Women's Hospital School Of Medicine Zhejiang University","100637456","rectosigmoid-lesion-excision-vs-resection-a-non-inferiority-randomized-comparison-in-advanced-ovarian-cancer-100637456",false,"NCT07616310","Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer","A Prospective Randomized Controlled Non-Inferiority Study Comparing the Efficacy of Lesion Excision Versus Rectosigmoid Resection in Pelvic Cytoreductive Surgery for Advanced Ovarian Cancer","RSEnTrail","Inclusion Criteria:\n\n* Voluntarily participate in this study and sign the informed consent form;\n* Age 18-70 years old;\n* Primary debulking surgery for epithelial ovarian cancer (including neoadjuvant chemotherapy), with or without abdominal and distant metastasis (≥ IIB stage);\n* Colonoscopy negative (no mucosal layer invasion);\n* Preoperative imaging (enhanced pelvic MRI) assesses the tumor's involvement of the intestinal surface and\u002For major parts of the mesentery;\n* Eastern Cooperative Oncology Group (ECOG) score \\\u003C 3;\n* American Society of Anesthesiologists (ASA) score \\\u003C 3.\n\nExclusion Criteria:\n\n* Has a history of other malignant tumors or is undergoing other anti-tumor treatments;\n* Has severe underlying medical conditions that make surgery intolerable;\n* Epithelial ovarian cancer diagnosed incidentally during emergency surgery;\n* Participates in other clinical studies simultaneously;\n* Secondary cytoreductive surgery for epithelial ovarian cancer;\n* Patients who have received radiotherapy to the abdomen or pelvis before.","FEMALE","18 Years","70 Years",{"count":87,"type":88},300,"ESTIMATED","INTERVENTIONAL",[91],"NA","Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized controlled studies comparing the oncological safety of these two surgical approaches. This study is a prospective randomized trial aimed at comparing the efficacy of rectosigmoid resection versus rectosigmoid-preserving lesion excision in advanced ovarian cancer surgery.",[94],"Ovarian Cancer (OvCa)",[15,9],"2026-05-29",{"date":98,"type":99},"2026-06-01","ACTUAL",{"date":101,"type":99},"2024-01-10",{"date":103,"type":88},"2028-12-31",{"name":5,"class":6},1]